The CDC’s Advisory Committee on Immunization Practices (ACIP) recently met to discuss Respiratory Syncytial Virus (RSV) vaccination recommendations. A common respiratory virus responsible for thousands of hospitalizations, RSV poses a serious risk to older adults.
ACIP stressed that whether a patient should receive an RSV vaccine depends on many factors, stating “For shared clinical decision-making recommendations there is no default.” In addition to their own clinical consideration, providers should consider evidence that supports benefit to the patient, the patient’s individual characteristics, values, and preferences, and characteristics of the RSV vaccine to be administered.
If a provider’s clinical decision is to provide an RSV vaccine, they should administer an FDA-approved RSV vaccine (GSK’s “Arexvy” or Pfizer’s “Abrysvo) as soon as supply is available.
To learn more about indications and read a brief overview of ACIP’s findings and recommendations, visit: www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/07-RSV-Adults-Britton-508.pdf
Comentários